What is Pharnext?
Pharnext SA is a French biopharmaceutical firm dedicated to developing innovative therapies for both orphan and common neurodegenerative diseases. The company's lead candidates include SYNGILITY, which has concluded Phase III trials for Charcot-Marie-Tooth disease type 1A, and PXT864, a compound that has completed Phase II clinical trials for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Pharnext also leverages its PLEOTHERAPY platform, an advanced system integrating big genetic data and artificial intelligence, to accelerate drug discovery and development. The company has also explored collaborations, such as its agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for COVID-19.
How much funding has Pharnext raised?
Pharnext has raised a total of $38.6M across 3 funding rounds:
Share Placement
$8.6M
Share Placement
$9.3M
Other Financing Round
$20.7M
Share Placement (2020): $8.6M, investors not publicly disclosed
Share Placement (2021): $9.3M, investors not publicly disclosed
Other Financing Round (2022): $20.7M supported by Néovacs
Key Investors in Pharnext
Néovacs
Néovacs is a biotechnology company focused on developing therapeutic vaccines for autoimmune diseases and cancer. Their participation suggests a strategic alignment with Pharnext's broader therapeutic goals.
What's next for Pharnext?
The substantial enterprise-level capital infusion and recent strategic investment signal a critical growth phase for Pharnext. This financing is poised to accelerate the clinical development of its promising drug candidates, particularly SYNGILITY and PXT864, through their later-stage trials and towards potential market approval. The company's focus on neurodegenerative diseases, a challenging but high-impact area, combined with its AI-driven PLEOTHERAPY platform, positions it for significant advancements. Future endeavors will likely involve expanding its research pipeline, forging strategic partnerships, and navigating the complex regulatory pathways inherent in biopharmaceutical development.
See full Pharnext company page
